Compositions and methods for treating cancer
View Patent ↗Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
1. A composition comprising a non-decitabine cytidine deaminase (CDA) substrate used for treating cancer and a compound of formula I:
wherein:
one of R 1 and R 2 is F, and the other is selected from H and F;
one of R 3 and R 4 is H, and the other is selected from H and OH;
where - - - is a covalent bond or absent, and R 4 is absent when - - - is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester or a C 2-6 alkenyl ester thereof.
2. The composition of claim 1 , wherein said non-decitabine CDA substrate is selected from the group consisting of 5-azacytidine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
3. The composition of claim 1 , wherein the compound of formula I is a compound of formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
4. A method of treating a cancer being treated with a non-decitabine CDA substrate used for treating cancer comprising:
administering to a subject a composition comprising a non-decitabine CDA substrate used for treating cancer; and
administering to a subject a composition comprising a compound of formula I:
wherein:
one of R 1 and R 2 is F, and the other is selected from H and F;
one of R 3 and R 4 is H, and the other is selected from H and OH;
where - - - is a covalent bond or absent, and R 4 is absent when - - - is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
5. The method of claim 4 , wherein said non-decitabine CDA substrate is selected from the group consisting of 5-azacytidine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
6. The method of claim 4 , wherein said cancer is selected from the group consisting of hematological cancers and solid cancers.
7. The method of claim 6 , wherein said cancer is a hematological cancer selected from the group consisting of myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia.
8. The method of claim 6 , wherein the cancer is a solid cancer selected from the group consisting of pancreatic cancer, ovarian cancer, peritoneal cancer, non small cell lung cancer, metastatic breast cancer, bladder cancer, transitional cell carcinoma, biliary tract cancer, gallbladder carcinoma, fallopian tube cancer, squamous cell carcinoma of the head and neck, hepatocellular carcinoma, liver tumor, lung carcinoma, uterine cervix tumor and colon cancer.
9. The method of claim 4 , wherein the compound is a compound of formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
10. The method of claim 9 , wherein said cancer is selected from the group consisting of hematological cancers and solid cancers.
11. The method of claim 10 , wherein said cancer is a hematological cancer selected from the group consisting of myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia.
12. The composition of claim 1 , wherein the non-decitabine CDA substrate is gemcitabine.
13. The composition of claim 12 , wherein the compound of formula I is a compound of formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
14. The method of claim 4 , wherein said non-decitabine CDA substrate is gemcitabine.
15. The method of claim 14 , wherein the compound is a compound of formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
16. A pharmaceutical composition comprising
(i) a non-decitabine CDA substrate used for treating cancer;
(ii) a compound of formula I:
wherein:
one of R 1 and R 2 is F, and the other is selected from H and F;
one of R 3 and R 4 is H, and the other is selected from H and OH;
where - - - is a covalent bond or absent, and R 4 is absent when - - - is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester or a C 2-6 alkenyl ester thereof; and
(iii) a pharmaceutically acceptable excipient.
17. The pharmaceutical composition of claim 16 , wherein said non-decitabine CDA substrate is selected from the group consisting of 5-azacytidine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, gemcitabine, and cytochlor.
18. A pharmaceutical composition of claim 16 , wherein the compound of formula I is a compound of formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester or a C 2-6 alkenyl ester thereof.
19. The method according to claim 4 , wherein the composition comprising a non-decitabine CDA substrate used for treating cancer and the composition comprising a compound of formula I are simultaneously administered.
20. The method according to claim 4 , wherein the composition comprising a non-decitabine CDA substrate used for treating cancer and the composition comprising a compound of formula I are sequentially administered.